When pharmaceutical companies are ready to ramp up the output of their products, they turn to BioVectra.
Organization: Pfizer
Precision NanoSystems receives federal support to build $50 million biomanufacturing facility in Vancouver
New plant expected to produce 240 million vaccine doses every year starting in 2023.
The Short Report – Nov. 11th, 2020: IRAP receives $155M for COVID-impacted firms; U of Calgary’s biosafety lab to reopen; and more…
A new pilot program matches researchers with priorities of the City of Toronto as part of the COVID-19 response effort and Polar Knowledge Canada has a new president.
The Short Report – Oct. 14, 2020: CIHR signs MOU to support Inuit-led health research, Health Canada accepts rolling submission for a COVID-19 vaccine candidate, and more
Facedrive’s TraceSCAN technology garners interest among companies globally; Canada’s National Digital Research Infrastructure Strategy has its first researcher council, and a new consortium takes shape to accelerate the commercialization of quantum computing.
Why Canada needs a national vaccine strategy
The private sector has little appetite for manufacturing small-volume, niche vaccines for pandemic viruses. That’s why any primary manufacturing facility for vaccines like COVID-19 need to be federally owned and operated.
Brain Canada & CQDM fund AbCellera’s cell screening platform technology
AbCellera Biologics Inc and the Univ of British Columbia (UBC) received non-dilutive funding of $1 million from pharma-based consortium CQDM and charitable organization Brain Canada Foundation to advance a discovery platform for next-generation antibody therapeutics. With the additional contribution of $450,000 from AbCellera, the program will leverage AbCellera’s high throughput, single-cell screening platform to allow rapid…